DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1003972
Title:
Treatment of Neuropathic Pain after SCI with a Catalytic Oxidoreductant
Descriptive Note:
Technical Report,30 Sep 2014,29 Sep 2015
Corporate Author:
University of Alabama at Birmingham Birmingham United States
Report Date:
2015-10-01
Pagination or Media Count:
48.0
Abstract:
The on-going research is to test the central hypothesis that post-SCI administration of the catalytic oxidoreductant BuOE will inhibit neuropathic pain after SCI. The research in years1 and 2 focused on the goal of aims 1 and 2, to test the hypothesis that post-SCI administration of BuOE decreases inflammation and ROS activation in a rat and mouse model of SCI. The main finding of our work in this year was to evaluate the dose-effect curve of post-SCI administration of BuOE on the outcomes listed above. Our data from on-going experiments indicate that the dose of 0.2mgkg BuOE was most effective in reducing inflammation and ROS activation acutely post-SCI in rats and mice. On-going experiments will evaluate additional outcome measures and behavioral outcomes in the subsequent year.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
